Mara Goldstein
Analyst, Mizuho Securities
Replay available
Fate Therapeutics, Inc. (NASDAQ: FATE) Q1 2023 earnings conference call, held 2023-05-03. Replay captured from the company's public earnings webcast.

Analyst, Mizuho Securities
President and CEO, Faith Therapeutics
Chief Research and Development Officer, Faith Therapeutics
Analyst, Bank of America
Analyst (on behalf of Peter Lawson, Barclays)
Analyst, SVB Securities
Analyst (on behalf of Gal, Citi)
Analyst (on behalf of Matt Bigler, Oppenheimer)
Analyst (on behalf of Jack Allen, Baird)
Analyst, Wells Fargo
Welcome to the Faith Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the investor section of Faith's website at faiththerapeutics.com. As a reminder, today's call is being recorded. I would now like to introduce Scott Walshco, President and CEO of Faith Therapeutics. Thank you. Good afternoon, and thanks, everyone, for joining us for the Faith Therapeutics first quarter 2023 financial results call. Shortly after 4 p.m. Eastern time today, we issued a press release with these results, which can be found on the investor section of our website under press releases. In addition, our form 10-Q for the quarter ended March 31, 2023, was filed shortly thereafter and can be found on the investor section of our website under financial information. Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Security Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statement disclaimer on the company's earnings press release issued after the close of market today, as well as the risk factors included in our Form 10-Q for the quarter ended March 31, 2023, that was filed with the SEC today. Undue reliance should not be placed on forward-looking statements which speak only as the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, Faith T...